Skip to main content

Table 1 Clinical characteristics stratified by disease at digital solution baseline

From: Implementation of a hybrid healthcare model in rheumatic musculoskeletal diseases: 6-months results of the multicenter Digireuma study

 

RA patients ( n  = 27)

SpA patients ( n  = 29)

Demographic and clinical features

 Sex (female)

20 (74.1)

14 (48.3)

 Age (years)

47.0 (13.2)

40.4 (6)

 Time since biologic onset (years)

7.9 (4.8)

5.8 (5.2)

 Smoking habit (ever smoker)

13 (50.0)

11 (42.3)

 RF positive

19 (70.4)

-

 ACPA positive

21 (77.8)

-

 HLA*B27 positive

-

14 (58.3)

Concomitant treatment

 csDMARDs

23 (85.2)

12 (44.4)

 Prednisone

11 (40.7)

0

  1. ACPA anti-citrullinated peptide antibodies, RF rheumatoid factor, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, SpA spondyloarthritis, RA rheumatoid arthritis. Results are expressed in median (IQR) and n (%)